Our Medical Approach
RxVigor connects patients with board-certified, state-licensed physicians who follow evidence-based protocols for GLP-1 prescribing. This page explains exactly how our clinical process works — including who we prescribe to and, just as importantly, who we don't.
Who Prescribes
All prescribing decisions at RxVigor are made by board-certified physicians licensed in the patient's state of residence. Our network includes physicians with backgrounds in internal medicine, family medicine, and endocrinology. No prescription is issued by a non-physician provider, and no prescription is issued without a documented clinical review of the patient's intake information.
Physicians are independent practitioners who exercise their own clinical judgment. RxVigor does not direct prescribing decisions — we provide the technology platform and pharmacy coordination.
How Prescribing Decisions Are Made
Every patient completes a structured health intake that covers current medications, relevant medical history, BMI, weight loss goals, and contraindications. Physicians review this information before making any prescribing decision. The review process includes:
- Contraindication screening — personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), pancreatitis history, and other GLP-1 contraindications
- Drug interaction review — current medications that may interact with GLP-1 agonists
- BMI and clinical eligibility — current guidelines require BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity
- Dose titration philosophy — physicians start patients at the lowest effective dose and titrate gradually to minimize side effects and improve tolerability
- Informed consent — patients are informed of the nature of compounded medications, expected outcomes, and potential side effects before treatment begins
Ongoing Care Standards
GLP-1 therapy is not a one-time prescription. Our clinical model includes structured follow-up to ensure patient safety and optimize outcomes:
Follow-Up Cadence
Patients are contacted at regular intervals to assess tolerability, side effects, and progress. Dose adjustments are made based on clinical response.
Dose Adjustments
Titration schedules are individualized. Physicians may slow titration, reduce dose, or pause treatment based on patient-reported side effects.
Side Effect Monitoring
Patients are educated on expected side effects (nausea, GI symptoms) and instructed to contact their provider for any serious or persistent symptoms.
Discontinuation Protocol
Patients who develop contraindications or experience serious adverse events are discontinued from treatment and referred to in-person care as appropriate.
Who We Do Not Prescribe To
We take contraindications seriously. The following patients are not eligible for GLP-1 therapy through RxVigor:
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- History of pancreatitis
- Pregnancy or active breastfeeding
- Type 1 diabetes
- Severe gastrointestinal disease (e.g., gastroparesis, inflammatory bowel disease in active flare)
- Known hypersensitivity to semaglutide, tirzepatide, or any component of the formulation
- BMI below 27 without a qualifying weight-related comorbidity
- Patients under 18 years of age
- Patients with certain kidney or liver conditions as determined by physician review
This list is not exhaustive. Physician discretion applies in all cases. Patients with complex medical histories are encouraged to consult their primary care provider before starting GLP-1 therapy.
Pharmacy Standards
All compounded medications dispensed through RxVigor are prepared by licensed, accredited compounding pharmacies operating under FDA oversight:
- 503A and 503B licensed compounding pharmacies — both categories are regulated by the FDA and subject to inspection
- Sterility and quality testing — all injectable compounded medications undergo sterility testing before release
- Cold-chain shipping — medications requiring refrigeration are shipped with appropriate cold-chain packaging
- No unapproved additives — formulations contain the active pharmaceutical ingredient (semaglutide or tirzepatide) without unapproved adjuvants or peptide blends
- Pharmacy credentials available upon request — patients may request pharmacy name and accreditation information
Important: Compounded GLP-1 medications are not FDA-approved drug products. They are prepared by licensed compounding pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Compounded medications may differ from FDA-approved brand-name products in formulation, appearance, and packaging.
Safety Monitoring Approach
Patient safety is the primary constraint on every clinical decision we make. Our safety monitoring approach includes:
- Structured intake screening to identify contraindications before any prescription is issued
- Patient education on expected side effects, warning signs, and when to seek emergency care
- Provider availability for follow-up questions and dose adjustment requests
- Clear escalation pathways — patients experiencing serious adverse events are directed to emergency services and their local primary care provider
- Adverse event documentation — serious adverse events are documented and reported in accordance with applicable regulations